Advances in Film Coating - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Advances in Film Coating

Pharmaceutical Technology Europe
Volume 26, Issue 8, pp. 30
PharmTech Europe 25th Anniversary
DSGpro/Getty Images;
Art direction: Dan Ward

Surveying the Landscape of Solid-Dosage Manufacturing

Experts take a look at the journey travelled thus far and where pharmaceutical manufacturing is heading over the next decade.

Film coating is a well-established unit operation in solid dosage form manufacture that offers many advantages for pharmaceutical products. Film coatings are applied onto tablets, multiparticulates and sometimes capsules or softgels to enhance their performance, protect the drug from the environment or achieve the desired immediate- (IR) or modified-release (MR) profile. Today, IR film coatings are most commonly used to impart a distinctive product appearance through colour and special effects, improve the ability to swallow and mask the unpleasant tastes or odours of drugs, as well as protect the drug from environmental factors.

Pharmaceutical Technology Europe
25th Anniversary Issue

Quality by Design—a Fundamental Paradigm Shift in Pharmaceutical Manufacturing

Tableting—a Focus for Continuous Improvement

Continuous Manufacturing—the Future of Pharmaceutical Manufacturing

Trends in Tablet Tooling

Polymers for Solubility Enhancement

In 1980, Colorcon first launched Opadry, a fully formulated, ready-to-use film coating, which reduces raw-material inventory and improves process efficiency, while delivering batch-to-batch colour consistency. Since then, fully formulated IR film coatings have advanced to include new polymer systems that offer greater manufacturing efficiencies and better core protection, and the innovations are ongoing.

Newer film coatings enhance the mechanical properties of the tablets for their handling during packaging and transport by companies and patients. The majority of IR film coatings contain cellulosic ethers, such as hypromellose (HPMC) or/and polyvinyl alcohol (PVA), as the main film formers, with pigments for colour and plasticiser to enable film formation. Although PVA is highly hydrophilic, when used in film coating, it provides effective moisture barrier properties.

Recently, the US FDA has been focusing on strategies to reduce the number of medication errors and improve patient compliance (1). The key features and properties of IR film coatings not only minimise the risks of medication errors, leveraging pigments and colour for identification, but also, improve patient compliance through aesthetic appeal and the ease of swallowing.

There has also been a surge of interest in the pharmaceutical market to protect the tablet composition from moisture while ensuring a high productivity coating process. To meet the challenge of moisture sensitive drugs while ensuring better stability of the overall formulations, it has become more important to select a more specialised coating system.

Continuous processing is fast emerging as a real asset to oral solid dosage manufacture. With the advancement of machinery and optimised excipients, including film coatings, continuous processing and manufacturing of drug products are becoming more viable, acceptable and realistic for the pharmaceutical industry. Film coating for solid oral dosage forms continues to provide important patient benefits while enhancing brand recognition and adding value to innovator, generic, over-the-counter and nutritional products.

1. FDA Guidance for Industry, Safety Considerations for Product Design to Minimise Medication Errors (Rockville, MD, Dec. 2012).

Ali Rajabi-Siahboomi
Ali Rajabi-Siahboomi

About the Author
Ali Rajabi-Siahboomi, PhD, is vice-president and chief scientific officer at Colorcon.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here